- For the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.
AND
AND
AND
Drug | Dosing Regimen | Dose Limit/ Maximum Dose |
---|---|---|
Zepatier | Genotype 1a: Treatment-naive or PegIFN/RBV experienced without baseline NS5A polymorphisms at amino acid positions 28, 30, 31, or 93 One tablet PO QD | 12 weeks |
Zepatier | Genotype 1b: | 12 weeks |
Zepatier + ribavirin | Genotype 1a: | 16 weeks |
Zepatier + ribavirin | Genotype 1a or 1b: | 12 weeks |
Drug | Dosing Regimen | Authorization Limit |
---|---|---|
Viekira Pak [dosed as (paritaprevir/ritonavir/ombitasvir) Two tablets PO QD Plus (dasabuvir) One tablet PO BID] | Genotype 1 CHC: | 12 weeks May be filled in quantities up to 28 days at a time |
Viekira Pak [dosed as (paritaprevir/ritonavir/ombitasvir) Two tablets PO QD Plus (dasabuvir) One tablet PO BID] | Genotype 1a, treatment naive or previous treatment with peg-interferon + ribavirin, with cirrhosis: | 24 weeks May be filled in quantities up to 28 days at a time |
Viekira Pak [dosed as (paritaprevir/ritonavir/ombitasvir) Two tablets PO QD Plus (dasabuvir) One tablet PO BID] | Genotype 1 CHC, Post liver transplant with normal liver function and mild fibrosis (F0 to F2): | 24 weeks May be filled in quantities up to 28 days at a time |